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condition in terms of disease burden, since it affects young people
affecting productivity with a high rate of disability. Hospitalisa-
tions are needed in almost 75% of patients and more than 3
times during disease evolution (mean 12 years). Further knowl-
edge about potentially preventable factors associated with sever-
ity and disease cost and burden would be of extreme value.
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OBJECTIVES: In the treatment of depression several antidepres-
sants are applied, mainly TZA, SSRI and SNRI. These sub-
stances have a different spectrum of activity and side effects,
particularly newer substances are often approved for speciﬁc
indications. Taking SNRI as an example, it is of interest in how
far the indication spectrum is therapeutically utilized by physi-
cians in everyday practice. METHODS: A retrospective cohort
study using claims data of a sickness fund, analysed beneﬁciaries
who received at least one SNRI prescription during the obser-
vation period from January 1, 2004 until December 31, 2004.
ICD-10 Codes from the ﬁeld of depression, anxiety and panic
patients, as well as affective disorders were clustered into diag-
nosis groups which represented potential ﬁelds of indication for
SNRI therapy. The distribution of diagnoses groups over the
indication spectrum was broken down into health care sectors
and represented and analyzed with the help of Venn diagrams.
RESULTS: From 1,478,978 beneﬁciaries n = 2,481 (0.17%) had
at least one prescription of Venlafaxin as the only available
SNRI in 2004. A total of 75.7% of them had a depression
diagnoses, 39.9% received SSRI for relapse prevention. From n
= 2,252 beneﬁciaries with a depression diagnosis and SNRI pre-
scriptions, A total of 22.8% have been treated due to indications
(depression in combination with anxiety) for which only Ven-
lafaxin has been approved. 39.7% have been treated due to an
indication (maintenance therapy and relapse prevention of
depressive disorders) for which besides Venlafaxin only Sertralin
was approved. CONCLUSIONS: One out of four depressive
patients treated currently with Venlafaxine could not be treated
with SSRIs due to the speciﬁc pharmacological proﬁle. Main-
taining the full spectrum of pharmacotherapy, in this example
Venlafaxine for treating depression, will enable physicians treat-
ing patients as adequate as possible to the individual patient’s
condition.
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OBJECTIVES: When patients do not respond to their initial
treatment, the physician can increase the initial dose, switch to
another treatment or add another treatment. This analysis aims
at comparing the different strategies after initiation of escitalo-
pram 10mg in patients treated for Major Depressive Disorder
(MDD). METHODS: Adult MDD patients initiated on escitalo-
pram 10mg, who either increased to 20mg (dose-increased
patients) or switched to (switchers) or were added another anti-
depressant (combination patients), were identiﬁed in the Phar-
Metrics US claims Database (2003–2006). Patients with early
dose increase (before 14 days) were excluded as it was consid-
ered as a scheduled dose titration. Patients’ characteristics at
treatment initiation and treatment outcomes three months after
treatment initiation were compared: treatment persistence or
change, health care resource use and associated costs. Multi-
variate regression analyses were performed to adjust for patient
characteristics and baseline resource use. RESULTS: A total of
8811 patients started with escitalopram 10 mg of which 51%
increased to 20 mg, 29% switched and 20% had a combina-
tion. Mean time to treatment change was 42 days for dose
increase, 36 days for switch (p < 0.001) and 30 days for com-
bination (p < 0.001). Three months after treatment initiation,
dose-increased patients had higher 3-month persistence com-
pared with switchers or combination patients, even when con-
sidering a time-event interaction. Switchers and combination
patients had a higher rate of subsequent/second switch and/or
combination (17.7% and 71.1% respectively), compared with
dose-increased patients (9.6%). Costs of both switchers and
combination patients were higher than those of dose-increased
patients (respectively: +US$124, adjusted RR = 1.1, 95%CI =
[1.0–1.2]; and +US$1060, adjusted RR = 1.3, 95%CI = [1.2–
1.5]). CONCLUSIONS: Increasing the dose of escitalopram
from 10 to 20mg was associated with fewer further changes in
treatment and with lower costs than switching or adding
another antidepressant. For patients who do not respond well to
their initial dose, dose increase should be considered before any
other strategy.
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OBJECTIVES: The study of new patients in a speciﬁc specialty
offered another insight into the epidemiology of diseases and the
mode of health care delivery. The aim of the study was to inves-
tigate the spectrum of diagnoses and medications among the
patients who visited the psychiatric clinics for the ﬁrst time in
Taiwan. METHODS: The data sources came from the historical
claims datasets of 1,000,000-person cohort from 1996 to 2006,
offered by the National Health Insurance Research Database in
Taiwan. The focus was on the patients who had never visited any
psychiatric clinic from 1996 to 2005 and had visited one in 2006.
The analyses of these patients’ ﬁrst visits included the distribu-
tions of the age, sex, primary diagnosis in codes of ICD-9-CM
(the International Classiﬁcation of Diseases, 9th Revision, Clini-
cal Modiﬁcation) and prescribed drugs classiﬁed into ATC (Ana-
tomical Therapeutic Chemical) codes. RESULTS: Among the
1,000,000-person cohort, 8,226 patients (4,393 females and
3,833 males; mean age 39.4  22.5 [SD] years) had their ﬁrst
visits to one of 330 psychiatric clinics in 2006. Among these new
patients, 1460 were under age 18 and 1352 over age 65. Neu-
rotic disorders (ICD-9-CM: 300) were most frequently seen diag-
noses in 3117 visits, followed by affective psychoses (296) in 918
visits and adjustment reaction (309) in 629 visits. The top 10
diagnostic groups accounted for 83.5% of all new visits. Medi-
cations had been prescribed in 6610 (80.3%) visits with an
average of 2.4  1.2 drug items. The most frequently prescribed
drug groups were antidepressants (ATC: N06A) in 3651 visits,
anxiolytics (N05B) in 3212 visits, hypnotics and sedatives
(N05C) in 3125 visits and antipsychotics (N05A) in 979 visits.
CONCLUSIONS: The people in Taiwan seemed unafraid of
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visiting psychiatrists. The issues of over-medication and polypsy-
chopharmacy deserve further attention.
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OBJECTIVES: Up to 75% of patients with bipolar disorder
report at least one lifetime hospitalization; patients treated with
second generation antipsychotics (SGAs) and mood stabilizers
(MS) are hospitalized more frequently than those treated with
MS monotherapy. It is not clear whether different SGAs differ-
entially reduce the risk of hospitalization in this at-risk popu-
lation, therefore the purpose of this study is to characterize
hospitalization rates in patients treated with adjunctive
SGA-MS combination therapy. METHODS: A retrospective
propensity score-matched cohort study was conducted in the
LabRx integrated claims database from January 2003 through
December 2006. Patients 18–65 with bipolar disorder and 180
days of pre-index enrollment without SGA therapy and 90 days
post-index enrollment were eligible for inclusion. MS therapy
was initiated within 30 days prior to or following index SGA
prescription. Multivariate logistic regression was used to esti-
mate the risk of hospitalization in patients treated with arip-
iprazole, olanzapine, quetiapine, risperidone, or ziprasidone
during the 90 day follow-up period. RESULTS: Of 7134
patients meeting inclusion criteria, 920 patients on aripiprazole
were matched to 920 on olanzapine, quetiapine, or risperidone,
while 518 aripiprazole patients were matched to 518 on
ziprasidone. Hospitalization rates in the ﬁrst 90 days following
index prescription was 9.3% (range 7.1–12.8%). Compared to
aripiprazole, patients on adjunctive SGAs demonstrated statis-
tically signiﬁcantly greater risks of hospitalization (olanzapine
OR 1.8, 95%CI 1.3, 2.7; quetiapine OR 1.5, 95%CI 1.1, 2.2;
risperidone OR 1.8, 95%CI 1.3, 2.6; ziprasidone OR 1.7,
95%CI 1.1, 2.7). CONCLUSIONS: Hospitalization in the ﬁrst
90 days following initiation of combination mood stabilizer-
SGA therapy is relatively common and inﬂuenced by choice of
SGA. This difference may be due to dosing and titration under
real world conditions.
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OBJECTIVES: Empirical studies show a severe undertreatment
of patients with Alzheimer’s disease in Germany. This compara-
tive online panel survey investigates potential causes for under-
treatment among general practitioners (GPs) and neurologists/
psychiatrists. METHODS: A total of 100 neurologists/
psychiatrists and 302 GPs were included in an online panel
survey. Participating GPs had experiences in treating diabetes,
asthma, depression, epilepsy, migraine and dementia; neurolo-
gists were experienced in schizophrenia, depression, epilepsy,
multiple sclerosis, migraine and dementia. Participants were
asked to compare these therapeutic areas in 8 items: urgency of
treatment, therapeutic options, difﬁculties in diagnosis, knowl-
edge on guidelines, difﬁculties in patient and care-giver commu-
nication, inﬂuence of budget restrictions, experiences in
switching therapy and referrals to specialists. A Likert-rating
scale (1–5) was used for assessing. An additional open question
addressed reasons for discontinuing therapy with antidementive
drugs. RESULTS: For Alzheimer’s disease GPs see lowest
urgency for treatment (2.2; 1.3 in diabetes), lowest number of
therapeutic options (3.5; 1.5 in asthma), largest difﬁculties in
diagnosis (3.3; 1.7 in diabetes), largest difﬁculties in patient and
care-giver communication (3.7; 1.9 in diabetes) and highest
budget restrictions (2.0; 2.8 in epilepsy). GPs’ knowledge of
guidelines is lowest in epilepsy (3.4) and dementia (3.0; 1.7 in
diabetes); their experience in therapeutic switches is lowest, the
number of referrals to specialists highest. Neurologists agree
with GPs that therapeutic options in dementia are lowest (3.5,
1.5 in schizophrenia) and budget pressure is highest (1.9; 2.7 in
epilepsy). They see a higher urgency of treatment for Alzheimer
and show more experience in treatment. Both groups agreed
that budget restraints are the most important reason for discon-
tinuing treatment with antidementive drugs. CONCLUSIONS:
Results suggest that budget constraints for GPs and
neurologists/psychiatrists are the dominant reason for under-
treatment of patients with Alzheimer’s disease. To ensure
evidence-based treatment with antidementive drugs in Germany
budget constraints need to be reduced.
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OBJECTIVES: Controlling pharmaceutical expenditures is of
particular interest to governments, as pharmaceuticals present
one of the main components of health care expenditures. Patent
expiries of drugs are important, as dispensing (cheaper) generic
drugs potentially results in lower pharmaceutical expenditures.
Therefore, modelling generic substitution patterns is highly rel-
evant as this can provide useful cost-cutting decision support.
The aim of this study was to model the duration until patients
switch from branded to generic drugs, in relation to various
inﬂuencing variables METHODS: Data were obtained from
Dutch pharmacy dispensing records from IADB.nl. We focused
on antidepressant prescription data. To identify a pattern on the
underlying diffusion process, the analysis was applied to four
antidepressants whose patent recently expired (ﬂuoxetine, par-
oxetine, citalopram, sertraline). Duration analysis techniques
were used to estimate the probability of patients to switch to a
generic drug over time, and to estimate the effect of different
covariates (e.g. patient, pharmacist and general practitioner char-
acteristics) on this switching probability. Since interval censored
data were used, discrete duration methods were applied which
resulted in the estimation of a binary regression model.
RESULTS: A higher probability for patients to switch from a
branded to a generic drug within the ﬁrst ﬁve months after patent
expiry was identiﬁed. Switching probabilities were mainly
affected by the general practitioners’ and pharmacists’ inclination
to provide generic drugs, the age, the experience of the patient on
the speciﬁc drug and the amount of different generic drugs intro-
duced in the market. CONCLUSIONS: Despite differences in
pharmacy dispensing patterns for different antidepressants
studied, we generally found common patterns in generic substi-
tution. Next to the inclination of health care professionals,
patient characteristics, time and the amount of available generic
alternatives affect generic substitution signiﬁcantly. However,
A598 Abstracts
